Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 177-184

  Robson, Joanna ^a,b   Doll, Helen ^c   Suppiah, Ravi ^d   Flossmann, Oliver ^e   Harper, Lorraine ^f   Höglund, Peter ^g   Jayne, David ^h   Mahr, Alfred ⁱ   Westman, Kerstin ^g   Luqmani, Raashid ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^e ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALOPECIA; ANCA ASSOCIATED VASCULITIS; ANGINA PECTORIS; ARTICLE; ATROPHY; AVASCULAR NECROSIS; BIRMINGHAM VASCULITIS ACTIVITY SCORE; BONE MARROW DEPRESSION; CATARACT; CEREBROVASCULAR ACCIDENT; CHEMICAL CYSTITIS; DIABETES MELLITUS; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGONADISM; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MICROSCOPIC POLYANGIITIS; MOUTH ULCER; NASAL CRUSTING; NOSE DISEASE; OBSERVATIONAL STUDY; OSTEOMYELITIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; VASCULITIS DAMAGE INDEX; WEAKNESS; WEGENER GRANULOMATOSIS; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; COMPLICATION; DISEASE COURSE; EUROPE; GRANULOMATOSIS WITH POLYANGIITIS; HEARING LOSS; MIDDLE AGED; NASAL OBSTRUCTION; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; DIABETES MELLITUS; DISEASE PROGRESSION; EUROPE; FEMALE; GLOMERULAR FILTRATION RATE; GRANULOMATOSIS WITH POLYANGIITIS; HEARING LOSS; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; NASAL OBSTRUCTION; NEOPLASMS; OSTEOPOROSIS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEINURIA; SEVERITY OF ILLNESS INDEX;

EID: 84918575913     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203927     Document Type: Article

References (29)

1. Jennette J, Falk R, Bacon P, et al. Revised international Chapel hill consensus conference nomenclature of Vasculitides. Arthritis Rheum 2012.
2. Flossmann O, Berden A, De Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94.
3. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
4. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43.
5. Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8.
6. Faurschou M, Mellemkjaer L, Sorensen IJ, et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009;60:1187-92.
7. Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011;63:588-96.
8. Merkel PA, Aydin SZ, Boers M, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 2011;38:1480-6.
9. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
10. Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM 1997;90:391-9.
11. Exley AR, Bacon PA, Luqmani RA, et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998;37:57-63.
12. Kamali S, Erer B, Artim-Esen B, et al. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients. J Rheumatol 2010;37:374-8.
13. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:572-81.
14. Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
15. Brijker F, Magee CC, Tervaert JW, et al. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies. Clin Nephrol 1999;52:344-51.
16. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
17. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol 1995;101(Suppl 1):29-34.
18. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
19. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
20. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
21. De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
22. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
23. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304:2381-8.
24. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
25. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
26. Flossmann O, Bacon P, De Groot K, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 2007;66:283-92.
27. Suppiah R, Flossman O, Mukhtyar C, et al. Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis 2011;70:80-5.
28. Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011;70:1415-21.
29. Bhamra K, Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep 2012;14:494-500.